產品描述: | Rigosertib (ON-01910) 是一種非ATP競爭性PLK1抑制劑,無細胞試驗中IC50為9 nM,比作用于Plk2選擇性高30倍,對Plk3沒有抑制活性。Rigosertib 可抑制 PI3K/Akt 信號通路并激活氧化應激信號。Rigosertib 可誘導多種癌細胞的凋亡。Phase 3 |
靶點: |
PLK1(Cell-free assay):9 nM; PDGFR(Cell-free assay):18 nM; Bcr-Abl(Cell-free assay):32 nM; Flt1(Cell-free assay):42 nM; Src(Cell-free assay):155 nM; Fyn(Cell-free assay):182 nM; CDK1(Cell-free assay):260 nM; PLK2(Cell-free assay):260 nM;PLK |
體外研究: |
ON01910, a small molecule inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. This compound was not ATP-competitive, but competed for the substrate binding site of the enzyme. |
體內研究: |
Rigosertib按250 mg/kg劑量作用于攜帶Bel-7402,MCF-7,和MIA-PaCa細胞的鼠移植瘤模型,明顯抑制腫瘤生長。Rigosertib按200 mg/kg劑量作用于攜帶BT20細胞的鼠移植瘤模型,也抑制腫瘤生長 |
細胞實驗: |
Cell lines: 多種腫瘤細胞系,包括 BT20,MCF-7,DU145,PC3,U87,A549,H187,RF1,HCT15,HeLa,和Raji細胞 Concentrations: 1 nM-10 μM, 溶于DMSO,作為儲存液 Incubation Time: 96小時 Method: 細胞生長在含10%FBS和1 unit/mL青霉素-鏈霉親和素溶液的DMEM或RPMI培養基中。腫瘤細胞按每孔1×105個細胞接種在6孔板上,24小時后,加入不同濃度Rigosertib。處理96小時后,測定每孔細胞數。通過臺酚藍染色測定全部存活細胞數 |
動物實驗: |
Animal Models: 攜帶Bel-7402,MCF-7,和MIA-PaCa細胞的雌性無胸腺NCR-nu/nu鼠 Dosages: 250 mg/kg Administration: 腹腔注射 |
參考文獻: |
1. Gumireddy K, et al. Cancer Cell, 2005, 7(3), 275-286. 2. Reddy MV, et al. J Med Chem, 2011, 54(18), 6254-6276. 3. Chapman CM, et al. Clin Cancer Res, 2012 18(7), 1979-1991. |
溶解性: |
Soluble in DMSO、H2O |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.112 ml |
10.56 ml |
21.121 ml |
5 mM |
0.422 ml |
2.112 ml |
4.224 ml |
10 mM |
0.211 ml |
1.056 ml |
2.112 ml |
50 mM |
0.042 ml |
0.211 ml |
0.422 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |